The preliminary analysis of the biology of the tumor allows to define at least three main therapeutic options: the least potentially effective treatment (CMF for basal-like, androgen inhibitor for LAR; etc...), the most effective conventional treatment (platinum-anthracycline-taxane for carriers of BRCA1/2 mutation/BRCA-like genomic instability signature, dose-dense anthracycline-taxane for the others), the combination of the second option with at least one experimental drug potentially active in that particular tumor (PARP/VEGF/PI3K/HDAC/etc-antagonist) (Table 3). This evidence concerns the gene BRCA1 and neoplasm.